Health Care · Pharmaceutical Preparations

RAPP Rapport Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 201259381 filings
Russell 2000

RAPP at a glance

Rapport Therapeutics, Inc. (RAPP, SEC CIK 2012593) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Rapport Therapeutics, Inc. (RAPP) shares worth $424.6 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by HEALY JAMES on October 28, 2026 of 952,380 shares at $21.00 per share.
  • In the last 90 days, RAPP insiders reported 11 open-market purchases ($22.0M) and 14 open-market sales ($4.5M) on Form 4, a net purchase of $17.6M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
11 buys · 14 sells
Net +$17.6M
13F holders
24 funds
$424.6M · −2 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue: $0, consistent with no product sales; nine-month collaboration revenue $20.0M vs $0
  • Operating margin: (100.0%) vs (100.0%) YoY, net loss $40.2M vs $26.9M
  • Worst performance: RAP-219 R&D costs $17.5M, up $8.7M YoY, driven by Phase 3 development
  • Cash, equivalents and short-term investments $395.0M; operating cash use $96.1M for nine months
  • Outlook: Phase 3 FOS trials enrolling; expenses expected to increase substantially; funding projected through 2029

Risk Factors

  • Newly expanded AI/ML risk: EU AI Act and emerging U.S. state laws could impose costly governance, transparency, monitoring and human-oversight requirements
  • Most materially updated regulatory risk: FDA’s June 2026 draft guidance may permit one pivotal trial, but FDA retains discretion to require additional clinical data
  • Privacy compliance exposure: GDPR penalties can reach €20 million or 4% of annual global revenues
  • Near-term clinical risk: RAP-219 Phase 3 programs face delays from enrollment, safety, efficacy or regulatory requirements
  • Financial risk: $172.5 million of 2.25% convertible senior notes mature in 2032

AI summary of the RAPP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results and business highlights announced for quarter ended September 30, 2026
  • Full financial figures and operating updates available in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Phase 2 bipolar mania success: 3.1-point placebo-adjusted YMRS improvement, supporting RAP-219 expansion beyond epilepsy
  • Safety favorable, but TEAE discontinuations 3.2% versus 0.8% for placebo
Filed Oct 30, 2026Full analysis →

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 links to Item 1.01, indicating a material financial obligation arose through an agreement
  • Investors should review Item 1.01 for obligation amount, payment terms, interest rate, maturity and use of proceeds

Item 3.02: Unregistered Sales of Equity Securities

  • PIPE shares sold privately to accredited investors under Section 4(a)(2) exemption
  • Shares unregistered, creating resale restrictions and potential future registration needs

Item 2.02: Results of Operations and Financial Condition

  • Preliminary cash, equivalents and short-term investments of approximately $395.0 million as of September 30, 2026
  • Liquidity disclosure accompanied underwritten offerings, potentially supporting ongoing clinical development and operations

Item 1.01: Entry into a Material Definitive Agreement

  • $215.7M net equity proceeds, including 11,190,476 shares or pre-funded warrants plus 1,428,571 exercised option shares
  • $166.8M net convertible-note proceeds, adding $172.5M principal at 2.25% interest due December 1, 2032
Filed Oct 20, 2026Full analysis →

Item 8.01: Other Events

  • Phase 2 met its primary endpoint: YMRS improvement 3.1 points versus placebo at Week 3, p=0.045
  • Secondary mania-severity endpoint also significant: 0.4-point improvement versus placebo, p=0.024

Item EX-99.1: Item EX-99.1

  • Phase 2 met primary and secondary endpoints: YMRS improvement 3.1 points versus placebo, p=0.045, CGI-BP improvement 0.4 points, p=0.024
  • RAP-219 reduced YMRS 15.4 points from baseline versus 12.3 points for placebo at Week 3

Item EX-99.2: Item EX-99.2

  • Phase 2 bipolar mania trial met primary and secondary endpoints, supporting RAP-219 advancement into Phase 3
  • YMRS improvement 3.1 points versus placebo at Week 3, p=0.045, with RAP-219 improvement of 15.4 points

Item 7.01: Regulation FD Disclosure

  • Positive topline Phase 2 results announced for RAP-219 in bipolar mania
  • Conference call and webcast scheduled October 20, 2026 to discuss trial data

AI summaries of RAPP 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for RAPP

Don't miss the next RAPP filing

  • Alerts as it files. A push when RAPP files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut RAPP, by share count.
  • Ask anything. An AI agent that reads every RAPP filing and answers with sources.

RAPP alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Third Rock Ventures V, L.P.AOct 30, 2026$21.00
Third Rock Ventures V, L.P.AOct 30, 2026$21.00
HEALY JAMESBuyOct 28, 2026$21.00
HEALY JAMESBuyOct 28, 2026$21.00
HEALY JAMESBuyOct 28, 2026$21.00
HEALY JAMESBuyOct 28, 2026$21.00
Sanchez RamiroBuyOct 23, 2026$27.35
Young Wendy B.BuyOct 22, 2026$26.39

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$36.2M-$83.1M-$125.1M
Net Income--$78.3M-$111.5M
Balance Sheet
Total Assets$155.4M$314.9M$512.4M
Equity-$25.6M$305.4M$484.7M
ROE--25.6%-23.0%
Per Share
EPS$-23.10$-3.78$-2.86
Cash Flow
Operating CF-$27.2M-$64.8M-$87.5M
CapEx$1.6M$2.4M$616K

Source: XBRL data in Rapport Therapeutics, Inc. (RAPP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate RAPP share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
RAPP shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$424.6M
Q2 202626$827.9M
Q1 202627$608.8M
Q4 202525$596.9M
Q3 202524$513.5M
Q2 202517$155.7M
Q1 202515$111.3M
Q4 20249$164.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 167 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

RAPP filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
4Nov 3, 2026--
4Oct 30, 2026--
8-KOct 30, 2026Analysis-
4Oct 23, 2026--
4Oct 23, 2026--
4Oct 22, 2026--
4Oct 22, 2026--
4Oct 22, 2026--
4Oct 22, 2026--
4Oct 21, 2026--
8-KOct 20, 2026Analysis-
4Oct 8, 2026--
4Oct 1, 2026--
4Sep 24, 2026--
4Sep 9, 2026--
4Aug 26, 2026--
4Aug 26, 2026--
4Aug 20, 2026--
4Aug 12, 2026--
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
4Jul 29, 2026--
4Jul 15, 2026--

Related Health Care companies

All Health Care →

RAPP SEC filings: frequently asked questions

Are RAPP insiders buying or selling?

In the last 90 days, Rapport Therapeutics, Inc. (RAPP) officers, directors and 10% owners reported 11 open-market purchases worth $22.0 million by 7 insiders and 14 open-market sales worth $4.5 million by 3 insiders on Form 4, a net purchase of $17.6 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold RAPP stock?

As of September 30, 2026, the largest Rapport Therapeutics, Inc. (RAPP) holders among the 13F filers tracked by SignalX were Goldman Sachs Group ($99.9 million), BlackRock ($96.8 million), Johnson & Johnson ($60.0 million), Vanguard Capital Management LLC ($53.1 million), State Street Corp ($30.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did RAPP report in its latest 8-K?

Rapport Therapeutics, Inc. (RAPP) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results and business highlights announced for quarter ended September 30, 2026.

What are the latest RAPP SEC filings?

Rapport Therapeutics, Inc. (RAPP) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 3, 2026.

What is RAPP's SEC CIK number?

Rapport Therapeutics, Inc. (RAPP)'s SEC Central Index Key (CIK) is 2012593. EDGAR lists every RAPP filing under that number.

Ask anything about RAPP

The research agent reads RAPP's filings, financials, insider trades and 13F holders, then answers with sources.